Yuichi Abe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yuichi Abe has a total of 156 co-authors. Here are the top co-authors by number of shared publications:
Itaru Hayakawa
Division of Neurology, National Center for Child Health and Development, Japan
5 shared publications- Itaru Hayakawa
Division of Neurology National Center for Child Health and development Tokyo Japan
5 shared publications - Akira Ohtake
Affiliations Department of Pediatrics, Saitama Medical University Hospital, Moroyama, Japan, Department of Clinical Genomics, Saitama Medical University Hospital, Moroyama, Japan
4 shared publications Hidehito Kondo
Affiliation Department of Pediatrics, Japanese Red Cross Society Kyoto Daiichi Hospital, Kyoto, Japan
3 shared publications- Hitoshi Nakagawa
Affiliation Department of Clinical Development, SBI Pharmaceuticals, Minato, Tokyo, Japan
3 shared publications - Motowo Nakajima
SBI Pharmaceuticals Co., Ltd., 1-6-1, Roppongi, Minato-ku, Tokyo 106-6019, Japan
3 shared publications
Latest Publications
- 7 November 2026
- Published by Wiley in Epileptic Disorders
Ketamine‐induced cholangiopathy in a child with febrile infection‐related epilepsy syndrome
- 7 November 2026
- Published by Wiley in Epileptic Disorders
Ketamine‐induced cholangiopathy in a child with febrile infection‐related epilepsy syndrome
- Open Access
- 31 August 2026
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 12 (3) , 71
Analytical Study Showing a False-Negative Limitation of Deletion-Based Newborn Screening for Spinal Muscular Atrophy Using a Compound Heterozygous SMN1 Control
Newborn screening (NBS) facilitates the presymptomatic diagnosis and early treatment of spinal muscular atrophy (SMA). An analytical study was conducted to evaluate the performance and limitations of a real-time polymerase chain reaction-based SMA-NBS assay. Dried blood spot specimens collected from 21 newborns and three patients with genetically confirmed SMA were analyzed. The SMA controls included two patients with homozygous SMN1 deletion and one with compound heterozygous SMN1 variants. SMN1 exon 7 copy numbers were quantified and interpreted. All newborn participants had SMN1 copy numbers above the screening cutoff value of 668 copies/µL and were classified as screening-negative. The two SMA controls with homozygous SMN1 deletion showed no detectable SMN1 amplification, which is consistent with positive screening results. In contrast, the compound heterozygous SMA control exhibited a mean SMN1 value of 7330 copies/µL, which was more than tenfold above the screening cutoff and would therefore have been classified as screening-negative; this value also fell within the range observed in the newborn cohort. This patient had a negative NBS result at birth despite subsequently developing genetically confirmed SMA. The SMA-NBS assay accurately detected patients with homozygous SMN1 deletion. However, it did not identify patients with compound heterozygous SMN1 variants. In conclusion, deletion-based SMA-NBS has an inherent false-negative limitation, and a negative screening result does not completely exclude an SMA diagnosis.
- 31 August 2026
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 12 (3) , 71
Open AccessAnalytical Study Showing a False-Negative Limitation of Deletion-Based Newborn Screening for Spinal Muscular Atrophy Using a Compound Heterozygous SMN1 Control
Newborn screening (NBS) facilitates the presymptomatic diagnosis and early treatment of spinal muscular atrophy (SMA). An analytical study was conducted to evaluate the performance and limitations of a real-time polymerase chain reaction-based SMA-NBS assay. Dried blood spot specimens collected from 21 newborns and three patients with genetically confirmed SMA were analyzed. The SMA controls included two patients with homozygous SMN1 deletion and one with compound heterozygous SMN1 variants. SMN1 exon 7 copy numbers were quantified and interpreted. All newborn participants had SMN1 copy numbers above the screening cutoff value of 668 copies/µL and were classified as screening-negative. The two SMA controls with homozygous SMN1 deletion showed no detectable SMN1 amplification, which is consistent with positive screening results. In contrast, the compound heterozygous SMA control exhibited a mean SMN1 value of 7330 copies/µL, which was more than tenfold above the screening cutoff and would therefore have been classified as screening-negative; this value also fell within the range observed in the newborn cohort. This patient had a negative NBS result at birth despite subsequently developing genetically confirmed SMA. The SMA-NBS assay accurately detected patients with homozygous SMN1 deletion. However, it did not identify patients with compound heterozygous SMN1 variants. In conclusion, deletion-based SMA-NBS has an inherent false-negative limitation, and a negative screening result does not completely exclude an SMA diagnosis.
- Open Access
- 17 July 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (7) , e0332283
A phase III double-blind, placebo-controlled, randomized withdrawal trial of 5‑aminolevulinic acid hydrochloride with sodium ferrous citrate for efficacy and safety in patients diagnosed as Leigh syndrome
Objective: A phase III, double-blind, placebo-controlled, randomized withdrawal trial of SPP‑004 (5‑aminolevulinic acid hydrochloride and sodium ferrous citrate) was conducted to confirm the efficacy and safety of SPP-004 for maintenance of clinical response in patients diagnosed with Leigh syndrome (LS) showing central nervous system disorders. Methods: Fifty-four patients entered a 24-week open-label period of SPP-004 administration. Among them, 28 patients who showed improvement on the Newcastle Paediatric Mitochondrial Disease Scale (NPMDS) for cranial nervous symptoms and myopathy symptoms proceeded to a 48-week double-blind (DB) period, where they were randomized (1:1) to receive SPP‑004 or placebo ( n = 14 each). Efficacy was evaluated using NPMDS for the full analysis set (FAS) during the DB‑period (SPP-004 n = 13, Placebo n = 14) and the entire study period ( n = 54). Safety evaluation focused on adverse events (AEs) in all 54 patients administered SPP-004. Results: The primary endpoint, the proportion of patients who discontinued due to inadequate efficacy at 48 weeks, was lower in the SPP-004 group (15.4% [95% CI: 1.9–45.4%]) compared to the placebo group (50.0% [23.0–77.0%]). Over 80% of the SPP-004 group showed maintained efficacy (p = 0.0486). All adverse drug reactions were mild, with no notable differences in AEs between groups. Conclusion: These findings suggest that SPP-004 is safe and may provide therapeutic effect for LS patients who achieved an initial clinical response.
- 17 July 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (7) , e0332283
Open AccessA phase III double-blind, placebo-controlled, randomized withdrawal trial of 5‑aminolevulinic acid hydrochloride with sodium ferrous citrate for efficacy and safety in patients diagnosed as Leigh syndrome
Objective: A phase III, double-blind, placebo-controlled, randomized withdrawal trial of SPP‑004 (5‑aminolevulinic acid hydrochloride and sodium ferrous citrate) was conducted to confirm the efficacy and safety of SPP-004 for maintenance of clinical response in patients diagnosed with Leigh syndrome (LS) showing central nervous system disorders. Methods: Fifty-four patients entered a 24-week open-label period of SPP-004 administration. Among them, 28 patients who showed improvement on the Newcastle Paediatric Mitochondrial Disease Scale (NPMDS) for cranial nervous symptoms and myopathy symptoms proceeded to a 48-week double-blind (DB) period, where they were randomized (1:1) to receive SPP‑004 or placebo ( n = 14 each). Efficacy was evaluated using NPMDS for the full analysis set (FAS) during the DB‑period (SPP-004 n = 13, Placebo n = 14) and the entire study period ( n = 54). Safety evaluation focused on adverse events (AEs) in all 54 patients administered SPP-004. Results: The primary endpoint, the proportion of patients who discontinued due to inadequate efficacy at 48 weeks, was lower in the SPP-004 group (15.4% [95% CI: 1.9–45.4%]) compared to the placebo group (50.0% [23.0–77.0%]). Over 80% of the SPP-004 group showed maintained efficacy (p = 0.0486). All adverse drug reactions were mild, with no notable differences in AEs between groups. Conclusion: These findings suggest that SPP-004 is safe and may provide therapeutic effect for LS patients who achieved an initial clinical response.
- 16 October 2025
- Published by Elsevier in Brain and Development
- Vol. 47 (6) , 104463
Response to the letter: “AESD and vitamin therapy: The need for biomarkers and follow-up”
- 16 October 2025
- Published by Elsevier in Brain and Development
- Vol. 47 (6) , 104463
Response to the letter: “AESD and vitamin therapy: The need for biomarkers and follow-up”
- Open Access
A phase III double-blind, placebo-controlled, randomized withdrawal trial of 5-aminolevulinic acid hydrochloride with sodium ferrous citrate for efficacy and safety in patients diagnosed as Leigh syndrome
Objective: A phase III, double-blind, placebo-controlled, randomized withdrawal trial of SPP-004 (5-aminolevulinic acid hydrochloride and sodium ferrous citrate) in patients diagnosed as Leigh syndrome (LS) was conducted to confirm the efficacy and safety of SPP-004 in patients with LS showing central nervous system disorders. Methods: Fifty-four patients entered a 24-week open-label period of SPP-004 administration. Among them, 28 patients showing improved scores on the Newcastle Paediatric Mitochondrial Disease Scale (NPMDS) for cranial nervous symptoms and myopathy symptoms proceeded to a 48-week double-blind (DB) period, where they were randomized (1:1) to receive SPP-004 or placebo ( n =14 each). Efficacy was evaluated using NPMDS for the full analysis set (FAS) during the DB-period (SPP-004 n =13, Placebo n =14) and the entire study period ( n =54). Safety evaluation focused on adverse events (AEs) in all 54 patients administered SPP-004. Results: The primary endpoint, the proportion of patients who discontinued due to inadequate efficacy at 48 weeks, was lower in the SPP-004 group (15.4% [95% CI: 1.9-45.4%]) compared to the placebo group (50.0% [23.0-77.0%]). Over 80% of the SPP-004 group maintained efficacy (p=0.0486). All adverse drug reactions were mild, with no notable differences in AEs between groups. Conclusion: These findings suggest that SPP-004 is safe and may provide therapeutic effect for LS symptoms.
Open AccessA phase III double-blind, placebo-controlled, randomized withdrawal trial of 5-aminolevulinic acid hydrochloride with sodium ferrous citrate for efficacy and safety in patients diagnosed as Leigh syndrome
Objective: A phase III, double-blind, placebo-controlled, randomized withdrawal trial of SPP-004 (5-aminolevulinic acid hydrochloride and sodium ferrous citrate) in patients diagnosed as Leigh syndrome (LS) was conducted to confirm the efficacy and safety of SPP-004 in patients with LS showing central nervous system disorders. Methods: Fifty-four patients entered a 24-week open-label period of SPP-004 administration. Among them, 28 patients showing improved scores on the Newcastle Paediatric Mitochondrial Disease Scale (NPMDS) for cranial nervous symptoms and myopathy symptoms proceeded to a 48-week double-blind (DB) period, where they were randomized (1:1) to receive SPP-004 or placebo ( n =14 each). Efficacy was evaluated using NPMDS for the full analysis set (FAS) during the DB-period (SPP-004 n =13, Placebo n =14) and the entire study period ( n =54). Safety evaluation focused on adverse events (AEs) in all 54 patients administered SPP-004. Results: The primary endpoint, the proportion of patients who discontinued due to inadequate efficacy at 48 weeks, was lower in the SPP-004 group (15.4% [95% CI: 1.9-45.4%]) compared to the placebo group (50.0% [23.0-77.0%]). Over 80% of the SPP-004 group maintained efficacy (p=0.0486). All adverse drug reactions were mild, with no notable differences in AEs between groups. Conclusion: These findings suggest that SPP-004 is safe and may provide therapeutic effect for LS symptoms.
- Open Access
- 9 August 2025
- Published by Elsevier in Brain and Development
- Vol. 47 (5) , 104415
Effect of vitamin administration on the prevention of acute encephalopathy with biphasic seizures and late reduced diffusion
- 9 August 2025
- Published by Elsevier in Brain and Development
- Vol. 47 (5) , 104415
Open AccessEffect of vitamin administration on the prevention of acute encephalopathy with biphasic seizures and late reduced diffusion
- Open Access
Efficacy and Safety of 5-Aminolevulinic Acid Hydrochloride Combined with Sodium Ferrous Citrate in Pediatric Patients with Leigh Syndrome and Central Nervous System Disorders: An Initial Exploratory Trial with a Double-Blind Placebo-Controlled Period, Followed by an Open-Label Period and a Subsequent Long-Term Administration Study
An explorative study was conducted to evaluate the efficacy and safety of 5-aminolevulinic acid hydrochloride combined with sodium ferrous citrate (SPP-004) in 10 pediatric patients with Leigh syndrome (LS) aged 3–24 months in 10 institutions between December 2014 and July 2019. The patients were randomized and allocated to the SPP-004 or placebo group for a 12-week double-blind period, followed by a 12-week open-label period with SPP-004 and then a long-term study of up to 180 weeks. The efficacy and safety were evaluated using the Newcastle Pediatric Mitochondrial Disease Scale (NPMDS) and adverse events (AEs), respectively. No significant differences were found between groups in NPMDS scores, but prolonged SPP-004 treatment stabilized or improved scores. During the initial double-blind phase, the serum lactate levels increased in the placebo group but not in the SPP-004 group. Over the period of prolonged treatment with SPP-004, the average serum lactate level gradually decreased to a normal level. One patient died due to heart failure, presumably due to an underlying disease. Overall, 7 out of 10 patients received SPP-004 without developing severe AEs until the termination of the long-term study. Given the severe symptoms and poor prognosis of pediatric LS, NPMDS scores were indicative of stabilization in pediatric LS patients treated with SPP-004.
Open AccessEfficacy and Safety of 5-Aminolevulinic Acid Hydrochloride Combined with Sodium Ferrous Citrate in Pediatric Patients with Leigh Syndrome and Central Nervous System Disorders: An Initial Exploratory Trial with a Double-Blind Placebo-Controlled Period, Followed by an Open-Label Period and a Subsequent Long-Term Administration Study
An explorative study was conducted to evaluate the efficacy and safety of 5-aminolevulinic acid hydrochloride combined with sodium ferrous citrate (SPP-004) in 10 pediatric patients with Leigh syndrome (LS) aged 3–24 months in 10 institutions between December 2014 and July 2019. The patients were randomized and allocated to the SPP-004 or placebo group for a 12-week double-blind period, followed by a 12-week open-label period with SPP-004 and then a long-term study of up to 180 weeks. The efficacy and safety were evaluated using the Newcastle Pediatric Mitochondrial Disease Scale (NPMDS) and adverse events (AEs), respectively. No significant differences were found between groups in NPMDS scores, but prolonged SPP-004 treatment stabilized or improved scores. During the initial double-blind phase, the serum lactate levels increased in the placebo group but not in the SPP-004 group. Over the period of prolonged treatment with SPP-004, the average serum lactate level gradually decreased to a normal level. One patient died due to heart failure, presumably due to an underlying disease. Overall, 7 out of 10 patients received SPP-004 without developing severe AEs until the termination of the long-term study. Given the severe symptoms and poor prognosis of pediatric LS, NPMDS scores were indicative of stabilization in pediatric LS patients treated with SPP-004.
- Open Access
- 21 July 2025
- Published by Wiley in Epilepsia Open
- Vol. 10 (5) , 1388-1395
Transition to Adult Care in Childhood‐Onset Epilepsy: A Retrospective Cohort Study at a Japanese Children's Hospital
Objective: Transitioning patients with childhood‐onset epilepsy to adult care is often challenging, particularly for those with complex medical or social backgrounds. This study aimed to identify key factors associated with a successful transfer to inform strategies that support continuity during this vulnerable period. Methods: A retrospective cohort study was conducted using medical records from the National Center for Child Health and Development, a tertiary pediatric hospital in Tokyo, Japan. Patients with epilepsy aged 18 years or older who had regular outpatient visits between January 1 and March 31, 2018, were enrolled and followed until June 30, 2022. Results: At the start of the study, 232 patients were identified, 225 patients were evaluated, and 186 (82.7%) were successfully transferred to adult care during the study period. The median age at transfer to adult care was 23 years. Successful transfer was significantly associated with epilepsy etiology, the presence of comorbidities, and support from transition services. Patients requiring assistance with daily living were more likely to transfer to neurologic non‐specialty care facilities, such as psychiatric clinics or home‐based care providers. Significance: Identifying factors associated with transition outcomes can help healthcare providers anticipate potential barriers and facilitate smoother transitions for patients with childhood‐onset epilepsy who require ongoing adult care. Plain Language Summary: We studied how young people with epilepsy move from children's hospitals to adult healthcare. Most patients successfully transitioned to adult care. During the observation period, transfer was more likely among those with different types of epilepsy and those who received support from transition services. Patients who were also seeing other medical departments tended to transfer less often. Our study highlights factors that may help plan better support for patients with childhood‐onset epilepsy.
- 21 July 2025
- Published by Wiley in Epilepsia Open
- Vol. 10 (5) , 1388-1395
Open AccessTransition to Adult Care in Childhood‐Onset Epilepsy: A Retrospective Cohort Study at a Japanese Children's Hospital
Objective: Transitioning patients with childhood‐onset epilepsy to adult care is often challenging, particularly for those with complex medical or social backgrounds. This study aimed to identify key factors associated with a successful transfer to inform strategies that support continuity during this vulnerable period. Methods: A retrospective cohort study was conducted using medical records from the National Center for Child Health and Development, a tertiary pediatric hospital in Tokyo, Japan. Patients with epilepsy aged 18 years or older who had regular outpatient visits between January 1 and March 31, 2018, were enrolled and followed until June 30, 2022. Results: At the start of the study, 232 patients were identified, 225 patients were evaluated, and 186 (82.7%) were successfully transferred to adult care during the study period. The median age at transfer to adult care was 23 years. Successful transfer was significantly associated with epilepsy etiology, the presence of comorbidities, and support from transition services. Patients requiring assistance with daily living were more likely to transfer to neurologic non‐specialty care facilities, such as psychiatric clinics or home‐based care providers. Significance: Identifying factors associated with transition outcomes can help healthcare providers anticipate potential barriers and facilitate smoother transitions for patients with childhood‐onset epilepsy who require ongoing adult care. Plain Language Summary: We studied how young people with epilepsy move from children's hospitals to adult healthcare. Most patients successfully transitioned to adult care. During the observation period, transfer was more likely among those with different types of epilepsy and those who received support from transition services. Patients who were also seeing other medical departments tended to transfer less often. Our study highlights factors that may help plan better support for patients with childhood‐onset epilepsy.
- Open Access
- 4 February 2024
- Published by Elsevier in Brain and Development Case Reports
- Vol. 2 (1)
Acute brainstem dysfunction in neonatal hyperammonemia with ornithine transcarbamylase deficiency: A case report
- 4 February 2024
- Published by Elsevier in Brain and Development Case Reports
- Vol. 2 (1)
Open AccessAcute brainstem dysfunction in neonatal hyperammonemia with ornithine transcarbamylase deficiency: A case report
- Open Access
- 3 January 2024
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 457, 122867
Clinical characteristics of SARS-CoV-2-associated encephalopathy in children: Nationwide epidemiological study
- 3 January 2024
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 457, 122867
Open AccessClinical characteristics of SARS-CoV-2-associated encephalopathy in children: Nationwide epidemiological study